Cargando…

Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment

BACKGROUND: Despite the worldwide campaigns of COVID-19 vaccinations, the pandemic is still a major medical and social problem. The Ortho VITROS SARS-CoV-2 spike-specific quantitative IgG (VITROS S-IgG) assay has been developed to assess neutralizing antibody (NT antibody) against SARS-CoV-2 spike (...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Maika, Saito, Kaori, Ai, Tomohiko, Nojiri, Shuko, Khasawneh, Abdullah, Paran, Faith Jessica, Horiuchi, Yuki, Takei, Satomi, Yamamoto, Takamasa, Wakita, Mitsuru, Hiki, Makoto, Miida, Takashi, Naito, Toshio, Takahashi, Kazuhisa, Tabe, Yoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873150/
https://www.ncbi.nlm.nih.gov/pubmed/36693058
http://dx.doi.org/10.1371/journal.pone.0279779
_version_ 1784877539885318144
author Takahashi, Maika
Saito, Kaori
Ai, Tomohiko
Nojiri, Shuko
Khasawneh, Abdullah
Paran, Faith Jessica
Horiuchi, Yuki
Takei, Satomi
Yamamoto, Takamasa
Wakita, Mitsuru
Hiki, Makoto
Miida, Takashi
Naito, Toshio
Takahashi, Kazuhisa
Tabe, Yoko
author_facet Takahashi, Maika
Saito, Kaori
Ai, Tomohiko
Nojiri, Shuko
Khasawneh, Abdullah
Paran, Faith Jessica
Horiuchi, Yuki
Takei, Satomi
Yamamoto, Takamasa
Wakita, Mitsuru
Hiki, Makoto
Miida, Takashi
Naito, Toshio
Takahashi, Kazuhisa
Tabe, Yoko
author_sort Takahashi, Maika
collection PubMed
description BACKGROUND: Despite the worldwide campaigns of COVID-19 vaccinations, the pandemic is still a major medical and social problem. The Ortho VITROS SARS-CoV-2 spike-specific quantitative IgG (VITROS S-IgG) assay has been developed to assess neutralizing antibody (NT antibody) against SARS-CoV-2 spike (S) antibodies. However, it has not been evaluated in Japan, where the total cases and death toll are lower than the rest of the world. METHODS: The clinical performance of VITROS S-IgG was evaluated by comparing with the NT antibody levels measured by the surrogate virus neutralizing antibody test (sVNT). A total of 332 serum samples from 188 individuals were used. Of these, 219 samples were from 75 COVID-19 patients: 96 samples from 20 severe/critical cases (Group S), and 123 samples from 55 mild/moderate cases (Group M). The remaining 113 samples were from 113 healthcare workers who had received 2 doses of the BNT162b2 vaccine. RESULTS: VITROS S-IgG showed good correlation with the cPass sVNT assay (Spearman rho = 0.91). Both VITROS S-IgG and cPass sVNT showed significantly higher plateau levels of antibodies in Group S compared to Group M. Regarding the humoral immune responses after BNT162b2 vaccination, individuals who were negative for SARS-CoV-2 nucleocapsid (N)-specific antibodies had statistically lower titers of both S-IgG and sVNT compared to individuals with a history of COVID-19 and individuals who were positive for N-specific antibodies without history of COVID-19. In individuals who were positive for N-specific antibodies, S-IgG and sVNT titers were similar to individuals with a history of COVID-19. CONCLUSIONS: Although the automated quantitative immunoassay VITROS S-IgG showed a reasonable correlation with sVNT antibodies, there is some discrepancy between Vitros S-IgG and cPass sVNT in milder cases. Thus, VITROS S-IgG can be a useful diagnostic tool in assessing the immune responses to vaccination and herd immunity. However, careful analysis is necessary to interpret the results.
format Online
Article
Text
id pubmed-9873150
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-98731502023-01-25 Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment Takahashi, Maika Saito, Kaori Ai, Tomohiko Nojiri, Shuko Khasawneh, Abdullah Paran, Faith Jessica Horiuchi, Yuki Takei, Satomi Yamamoto, Takamasa Wakita, Mitsuru Hiki, Makoto Miida, Takashi Naito, Toshio Takahashi, Kazuhisa Tabe, Yoko PLoS One Research Article BACKGROUND: Despite the worldwide campaigns of COVID-19 vaccinations, the pandemic is still a major medical and social problem. The Ortho VITROS SARS-CoV-2 spike-specific quantitative IgG (VITROS S-IgG) assay has been developed to assess neutralizing antibody (NT antibody) against SARS-CoV-2 spike (S) antibodies. However, it has not been evaluated in Japan, where the total cases and death toll are lower than the rest of the world. METHODS: The clinical performance of VITROS S-IgG was evaluated by comparing with the NT antibody levels measured by the surrogate virus neutralizing antibody test (sVNT). A total of 332 serum samples from 188 individuals were used. Of these, 219 samples were from 75 COVID-19 patients: 96 samples from 20 severe/critical cases (Group S), and 123 samples from 55 mild/moderate cases (Group M). The remaining 113 samples were from 113 healthcare workers who had received 2 doses of the BNT162b2 vaccine. RESULTS: VITROS S-IgG showed good correlation with the cPass sVNT assay (Spearman rho = 0.91). Both VITROS S-IgG and cPass sVNT showed significantly higher plateau levels of antibodies in Group S compared to Group M. Regarding the humoral immune responses after BNT162b2 vaccination, individuals who were negative for SARS-CoV-2 nucleocapsid (N)-specific antibodies had statistically lower titers of both S-IgG and sVNT compared to individuals with a history of COVID-19 and individuals who were positive for N-specific antibodies without history of COVID-19. In individuals who were positive for N-specific antibodies, S-IgG and sVNT titers were similar to individuals with a history of COVID-19. CONCLUSIONS: Although the automated quantitative immunoassay VITROS S-IgG showed a reasonable correlation with sVNT antibodies, there is some discrepancy between Vitros S-IgG and cPass sVNT in milder cases. Thus, VITROS S-IgG can be a useful diagnostic tool in assessing the immune responses to vaccination and herd immunity. However, careful analysis is necessary to interpret the results. Public Library of Science 2023-01-24 /pmc/articles/PMC9873150/ /pubmed/36693058 http://dx.doi.org/10.1371/journal.pone.0279779 Text en © 2023 Takahashi et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Takahashi, Maika
Saito, Kaori
Ai, Tomohiko
Nojiri, Shuko
Khasawneh, Abdullah
Paran, Faith Jessica
Horiuchi, Yuki
Takei, Satomi
Yamamoto, Takamasa
Wakita, Mitsuru
Hiki, Makoto
Miida, Takashi
Naito, Toshio
Takahashi, Kazuhisa
Tabe, Yoko
Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment
title Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment
title_full Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment
title_fullStr Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment
title_full_unstemmed Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment
title_short Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment
title_sort performance evaluation of the ortho vitros sars-cov-2 spike-specific quantitative igg test by comparison with the surrogate virus neutralizing antibody test and clinical assessment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873150/
https://www.ncbi.nlm.nih.gov/pubmed/36693058
http://dx.doi.org/10.1371/journal.pone.0279779
work_keys_str_mv AT takahashimaika performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT saitokaori performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT aitomohiko performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT nojirishuko performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT khasawnehabdullah performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT paranfaithjessica performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT horiuchiyuki performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT takeisatomi performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT yamamototakamasa performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT wakitamitsuru performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT hikimakoto performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT miidatakashi performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT naitotoshio performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT takahashikazuhisa performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment
AT tabeyoko performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment